Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
55.78 USD | +1.30% | +3.54% | -10.83% |
18/04 | Citigroup Adjusts CRISPR Therapeutics' Price Target to $89 From $88, Keeps Buy Rating | MT |
17/04 | Crispr Therapeutics Insider Sold Shares Worth $1,173,232, According to a Recent SEC Filing | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.83% | 4.67B | |
+24.62% | 48.09B | |
+46.90% | 40.62B | |
-3.22% | 40.43B | |
-6.20% | 28.36B | |
+9.34% | 24.89B | |
-20.56% | 19.01B | |
+28.55% | 12.09B | |
+0.45% | 11.88B | |
-1.07% | 11.8B |
- Stock Market
- Equities
- CRSP Stock
- News CRISPR Therapeutics AG
- CRISPR Therapeutics : Needham Adjusts CRISPR Therapeutics' Price Target to $170 From $105, Keeps at Buy